TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
Clinical trial NCT05314101 · UNKNOWN
Trial details
- NCT number
- NCT05314101
- Sponsor
- Fujian Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-01
- Primary completion
- 2023-02-28
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.